|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, klotho attenuated diabetic nephropathy in db/db mice, which was also associated with inhibition of the Wnt/β-catenin pathway and RAAS.
|
30784349 |
2020 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We thus present convincing evidence demonstrating CRP as a therapeutic target for DKD treatment.-Zhang, L., Shen, Z.-Y., Wang, K., Li, W., Shi, J.-M., Osoro, E. K., Ullah, N., Zhou, Y., Ji, S.-R. C-reactive protein exacerbates epithelial-mesenchymal transition through Wnt/β-catenin and ERK signaling in streptozocin-induced diabetic nephropathy.
|
30794428 |
2019 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant activation of the Wnt/β-catenin pathway contributes to the development of diabetic nephropathy (DN); however, treatment with <i>Tripterygium wilfordii</i> (TW) may be beneficial for patients with DN.
|
29581743 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS These results provide a molecular pathomechanism of β-arrestin 1/2 and Wnt/β-catenin pathway on podocyte apoptosis and provide new ideas for the treatment of diabetic nephropathy, which paves the way for the future study of diabetic nephropathy and podocytes.
|
29572435 |
2018 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, blocking CTGF by specific antibody reduced albuminuria, prevented the overexpression of CTGF, as well as β-catenin, in glomeruli and subsequently ameliorated podocyte EMT in DN mice.
|
28370212 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-27a (miR-27a), peroxisome proliferator-activated receptor γ (PPARγ) and β-catenin pathways have been involved in the pathogenesis of DN.
|
28277542 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose an epigenetic process via the WT1/EZH2/β-catenin axis in attenuating podocyte injury in DN.
|
28315733 |
2017 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
WNT/β-catenin pathway members have been implicated in interstitial fibrosis and glomerular sclerosis disease processes characteristic of diabetic nephropathy (DN), processes partly controlled by transcription factors (TFs) that bind to gene promoter regions attenuating regulation.
|
26697505 |
2016 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
All the findings manifested that Wnt/β-catenin/UCH-L1 may be a new potential therapy method in the treatment of DN in future.
|
27571062 |
2016 |
|
Diabetic Nephropathy
|
0.100 |
Biomarker
|
disease |
BEFREE |
This information provides a novel molecular target of Wnt/β-catenin for the protection of kidney damage and in delay of the progression of DN.
|
24455745 |
2013 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that analysed common variants in CTNNB1, AXIN2, LRP5 and LRP6 are not strongly associated with diabetic nephropathy in type 1 diabetes among white individuals.
|
21876774 |
2011 |
|
Diabetic Nephropathy
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mice with podocyte-specific deletion of Ctnnb1 or podocyte-specific expression of the canonical Wnt inhibitor Dickkopf-related protein 1 (Dkk1) also showed increased susceptibility to DKD.
|
21613219 |
2011 |